Monitoring therapeutic effects in experimental stroke by serial USPIO-enhanced MRI - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Radiology Année : 2012

Monitoring therapeutic effects in experimental stroke by serial USPIO-enhanced MRI

Résumé

OBJECTIVES: This study sought to evaluate whether the therapeutic effects of an anti-inflammatory drug such as minocycline could be monitored by serial ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI in experimental stroke. METHODS: Mice received a three-dose minocycline treatment (n = 12) or vehicle (n = 12) after permanent middle cerebral artery occlusion. USPIOs were administered 5 h post-surgery. MRI was performed before, 24 h and 48 h post-USPIO administration. MRI endpoints were the extent of signal abnormalities on R2 maps (=1/T2) and quantitative R2 changes over time (∆R2). Post-mortem brains were prepared either for immunohistology (n = 16) or for iron dosage (n = 8). RESULTS: As expected, treatment with minocycline significantly reduced infarct size, blood-brain barrier permeability and F4/80 immunostaining for microglia/macrophages. Areas of R2 maps > 35 ms(-1) also appeared significantly decreased in minocycline-treated mice (ANOVA for repeated measures, P = 0.017). There was a fair correlation between these areas and the amount of iron in the brain (R(2) = 0.69, P = 0.010), but no significant difference in ∆R2 was found between the two groups. CONCLUSIONS: This study showed that the extent of signal abnormalities on R2 maps can be used as a surrogate marker to detect minocycline effects in a murine experimental model of stroke.

Dates et versions

hal-00797957 , version 1 (07-03-2013)

Identifiants

Citer

M. Marinescu, F. Chauveau, A. Durand, Agathe Riou, T.-H. Cho, et al.. Monitoring therapeutic effects in experimental stroke by serial USPIO-enhanced MRI. European Radiology, 2012, 23 (1), pp.37-47. ⟨10.1007/s00330-012-2567-2⟩. ⟨hal-00797957⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More